Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03482882 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression
A Phase 2 study of Treatment of Depression in Adults With Parkinson's Disease (PD), sponsored by ACADIA Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 20
- Study locations
NCT03482882: Completed Phase 2 study of Treatment of Depression in Adults With Parkinson's Disease (PD), sponsored by ACADIA Pharmaceuticals.
NCT03482882 is a Phase 2 study of Treatment of Depression in Adults With Parkinson's Disease (PD) that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 47 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03482882, a Phase 2 study of Treatment of Depression in Adults With Parkinson's Disease (PD), has completed, sponsored by ACADIA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy of pimavanserin for the treatment of depression in adults with Parkinson's disease.
Primary Outcome
The HAMD-17 is a multiple-item questionnaire to assess the severity of depression, including items of mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. Each of the 17 items is scored on a 3- or 5-point scale (depending on the item). The minimum total score is 0; the maximum total score is 52. A higher total score signifies more severe depression.
Conditions Studied
Interventions
- DRUG Pimavanserin
Study Locations (20)
California
- ATP Clinical Research, Inc. - Costa Mesa
- The Parkinson's and Movement Disorder Institute - Fountain Valley
- SC3 Research-Reseda - Pasadena
- The Neurology Group - Pomona
- SC3 Research-Reseda - Reseda
- CNS Network - Torrance
Florida
- Parkinson's Disease and Movement Disorder Center of Boca Raton - Boca Raton
- University of Florida - Gainesville
- Parkinson's Disease Treatment Center of SW Florida - Port Charlotte
- Infinity Clinical Research, LLC - Sunrise
- Tallahassee Neurological Clinic, P.A. - Tallahassee
New York
- Albany Medical College - Albany
- David L. Kreitzman, MD, PC - Commack
Connecticut
- Associated Neurologists, P.C. - Danbury
Michigan
- SRI Biosciences, Clinical Trials and Strategic Development Services - Plymouth
Missouri
- Washington University School of medicine - St Louis
New Jersey
- Bio Behavioral Health - Toms River
North Carolina
- Asheville Neurology Specialists, PA - Asheville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2018-03-09 |
| Est. Completion | 2019-07-24 |
| Phase | Phase 2 |
What the finished NCT03482882 record still lists
NCT03482882 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Treatment of Depression in Adults With Parkinson's Disease (PD) appearing as the primary indexed condition, and to 1 intervention - of which Pimavanserin is the first listed.
NCT03482882 names 20 study sites across 10 states, led by California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT03482882 about?
NCT03482882 is a clinical study titled "Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression". The purpose of this study is to assess the efficacy of pimavanserin for the treatment of depression in adults with Parkinson's disease.
What is the current status of trial NCT03482882?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2018-03-09. Estimated completion is 2019-07-24.
What conditions does trial NCT03482882 study?
This clinical trial studies the following conditions: Treatment of Depression in Adults With Parkinson's Disease (PD).
What interventions are being tested in trial NCT03482882?
The interventions under investigation include: Pimavanserin (DRUG).
Who is sponsoring clinical trial NCT03482882?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03482882 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03482882's enrollment target sits among peer trials
47 1283rd of 2000 higher than 715 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI